Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer
Colorectal Cancer
DRUG: Fruquintinib|DRUG: Cadonilimab|RADIATION: SBRT
Progression-free survival (PFS), To assess the efficacy of Cadonilimab Combined With Fruquintinib and SBRT for patients with advanced colorectal cancer by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)., up to 42 months
Objective response rate (ORR), CR + PR rate according to the RECIST version 1.1 guidelines., up to 42 months|Disease control rate (DCR), Disease control rate (DCR):CR + PR + SD rate according to the RECIST version 1.1 guidelines., up to 42 months|Overall survival (OS), The time interval between the start date of study drug and the date of death (any cause), until death|quality of life (QOL), QOL according to QOL-C30, up to 42 months|AEs, Adverse reactions refer to the occurrence and development of diseases in the process of using drugs according to normal usage and dosage to prevent, diagnose or treat diseases.Adverse reactions unrelated to the purpose of treatment., up to 42 months
A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer